Genentech × Hanmi Pharmaceutical Co., Ltd.
Genentech, a member of the Roche Group, licensed Hanmi Pharm's clinical-stage obesity drug candidate, HM17321. [47] Hanmi will receive $190 million upfront, with the total deal value potentially reaching $2.3 billion through development, regulatory, and commercial milestones, plus tiered royalties on sales. [54] Hanmi will complete the ongoing Phase 1 trial, after which Genentech will take over all development from Phase 2 onwards. [43, 46]
The asset
Exclusive worldwide license (excluding South Korea) for the development, manufacturing, and commercialization of HM17321, a novel, non-incretin, UCN2 analog candidate for obesity and associated metabolic diseases.
The record
- Seller status
- Going concern
- Sector
- pharmaceuticals
- Modalities
- clinical_trial_data, preclinical_data
- Jurisdiction
- US
- Personal data
- Data pertains to preclinical studies and a Phase 1 clinical trial on human volunteers; specific PII treatment is not detailed in sources but is governed by clinical trial regulations.
What it means if you hold data
This is a major investment in a non-GLP-1 obesity therapy, signaling strong interest in alternative mechanisms that may preserve muscle mass. [47, 54] The deal structure, with a large upfront payment for a Phase 1 asset, highlights the high value placed on promising clinical data in the metabolic disease space.